Minerva Neurosciences, Inc. (NERV) Stock Forecast
NERV analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 3 analysts
- Price target
- $10.33 average of analyst targets
- Upside to target
- +339.7% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.14
- 52-week range
- $2.35 – $8.07
NERV analyst ratings
3 analystsNumber of analysts at each rating.
NERV price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NERV earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.22 | −$0.14 | −$0.36 | +50.0% | 2 |
| Current fiscal year (2026) | −$0.57 | −$0.57 | −$0.57 | −$1.89 | +69.8% | 1 |
| Next fiscal year (2027) | −$0.42 | −$0.42 | −$0.42 | −$0.57 | +26.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NERV revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
NERV EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NERV EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.23 | −$0.23 | −$0.23 | −$0.23 | −$0.18 | −20.0% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.60 | −$0.20 | −$0.20 | −$0.20 | −$0.57 | −5.0% | 1 up · 0 down |
| Next fiscal year (2027) | −$0.48 | $0.00 | $0.00 | $0.00 | −$0.42 | −12.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NERV earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NERV beat in 5 of 12.
What analysts expect from NERV
3 analysts cover Minerva Neurosciences; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.33, 339.7% above the latest close of $2.35. Analysts expect earnings of −$0.57 per share for 2026, +69.8% from a year earlier. For 2027 the average estimate is −$0.42 per share. Minerva Neurosciences beat the EPS estimate in 5 of the last 12 quarters.
Related: NERV income statement, NERV key metrics, NERV chart. See the NERV stock overview for the latest quote and news.
NERV forecast FAQ
What is Minerva Neurosciences's price target?
The average analyst price target for Minerva Neurosciences is $10.33, 339.7% above the latest close of $2.35.
Is Minerva Neurosciences a buy, hold or sell?
Of 3 analysts covering Minerva Neurosciences, 1 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Minerva Neurosciences's EPS forecast?
Analysts forecast −$0.57 per share for 2026 (range −$0.57 to −$0.57); for 2027 the estimate is −$0.42.
When does Minerva Neurosciences report earnings?
Minerva Neurosciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.14.
Does Minerva Neurosciences usually beat earnings estimates?
Minerva Neurosciences reported EPS at or above the analyst estimate in 5 of the last 12 quarters.